sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Interests in Avadel Pharmaceuticals
The Vanguard Group, Inc. has filed a Form 8.3 disclosure with the Irish Takeover Panel regarding its interests in Avadel Pharmaceuticals plc. As of December 1, 2025, Vanguard holds 5,581,777 US$0.01 ordinary shares, amounting to a 5.73% stake in Avadel. Notably, no derivatives or options were exercised in conjunction with this interest, and no related agreements have been reported.
The filing also details recent transactions involving Avadel's securities. Vanguard purchased 2,982 shares at USD 21.42 each and sold 67 shares at the same price. The disclosure confirms no other inducement agreements or derivative-related understanding were in place.
This move falls under Rule 8.3 of the Irish Takeover Rules, emphasizing transparency by those holding significant positions in relevant securities.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.